

METFORMIN HCl

xxxxxxxx-5343

METTA SR 500 mg Extended-Release Tablet Oral Hypoglycemic

FORMULATION:

Each extended-release tablet contains:
Metformin HCl, USP 500 mg

PRODUCT DESCRIPTION

Metformin Hydrochloride (Metta SR) 500 mg Extended-Release Tablet is a white to off-white colored, capsule shaped, biconvex tablets with "Torrent logo" debossed on one side and '500' on the other side.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics:

Metformin is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.

Metformin may act via 3 mechanisms:

1. Reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
2. In muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization
3. Delay of intestinal glucose absorption.

Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.

Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).

In clinical studies, the major non glycaemic effect of metformin is either weight stability or modest weight loss.

In humans, independently of its action on glycaemia, metformin has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: Immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the extended-release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.

Clinical efficacy :

The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:

- a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.
 - a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;
 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);
 - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01)
- For metformin used as second-line therapy, in combination with a sulphonylurea, benefit regarding clinical outcome has not been shown.

In type 1 diabetes, the combination of metformin and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established.

Pharmacokinetics

Absorption

After an oral dose of the prolonged release tablet, metformin absorption is significantly delayed compared to the immediate release tablet with a Tmax at 7 hours (Tmax for the immediate release tablet is 2.5 hours).

At steady state, similar to the immediate release formulation, Cmax and AUC are not proportionally increased to the administered dose. The AUC after a single oral administration of 2000mg of metformin prolonged release tablets is similar to that observed after administration of 1000mg of metformin immediate release tablets b.i.d.

Intrasubject variability of Cmax and AUC of metformin prolonged release is comparable to that observed with metformin immediate release tablets.

When the prolonged release tablet is administered in fasting conditions the AUC is decreased by 30% (both Cmax and Tmax are unaffected).

Mean metformin absorption from the prolonged release formulation is almost not altered by meal composition.

No accumulation is observed after repeated administration of up to 2000mg of metformin as prolonged release tablets.

Following a single oral administration of 1500 mg of Metformin SR 750 mg, a mean peak plasma concentration of 1193 ng/ml is achieved with a median value of 5 hours and a range of 4 to 12 hours.

Metformin SR 750 mg was shown to be bioequivalent to Metformin SR 500 mg at a 1500 mg dose with respect to Cmax and AUC in healthy fed and fasted subjects.

Following a single oral administration in the fed state of one tablet of Metformin SR 1000 mg, a mean peak plasma concentration of 1214 ng/ml is achieved with a median time of 5 hours (range of 4 to 10 hours).

Metformin SR 1000 mg was shown to be bioequivalent to Metformin SR 500 mg at a 1000 mg dose with respect to Cmax and AUC in healthy fed and fasted subjects.

When the 1000 mg prolonged release tablet is administered in fed conditions the AUC is increased by 77% (Cmax is increased by 26% and Tmax is slightly prolonged by about 1 hour).

Distribution

Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean Vd ranged between 63-276 L.

Metabolism

Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.

Elimination

Renal clearance of metformin is > 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.

When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.

INDICATION:

As monotherapy, it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. May be used concomitantly with sulfonylureas or insulin to improve glycaemic control.

DOSAGE AND ADMINISTRATION:

Monotherapy and combination with other oral antidiabetic agents:

- The usual starting dose is one tablet of Metformin SR 500 mg once daily.
- After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets of Metformin SR 500 mg daily.

- Dosage increases should be made in increments of 500 mg every 10-15 days, up to a maximum of 2000 mg once daily with the evening meal. If glycaemic control is not achieved on Metformin SR 2000 mg once daily, Metformin SR 1000 mg twice daily should be considered, with both doses being given with food. If glycaemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.

- In patients already treated with metformin tablets, the starting dose of Metformin SR should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to Metformin SR is not recommended.

- If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate Metformin SR at the dose indicated above.

- Metformin SR 750 mg is intended for patients who are already treated with metformin tablets (prolonged or immediate release).

- The dose of Metformin SR 750 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 1500 mg, given with the evening meal.

Combination with insulin:

Metformin and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of Metformin SR is one 500 mg tablet once daily, while insulin dosage is adjusted on the basis of blood glucose measurements.

For patients already treated with metformin and insulin in combination therapy, the dose of Metformin SR 750 mg should be equivalent to the daily dose of metformin tablets up to a maximum of 1500 mg, given with the evening meal, while insulin dosage is adjusted on the basis of blood glucose measurements.

Elderly: due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.

Children: In the absence of available data, Metformin SR should not be used in children.

CONTRAINDICATIONS:

1. Hypersensitivity to metformin hydrochloride or to any of the excipients.
2. Diabetic ketoacidosis, diabetic pre-coma.
3. Renal failure or renal dysfunction (creatinine clearance < 60 ml/min).
4. Acute conditions with the potential to alter renal function such as:
 - dehydration,
 - severe infection,
 - shock,
5. Acute or chronic disease which may cause tissue hypoxia such as:
 - cardiac or respiratory failure,
 - recent myocardial infarction,
 - shock
6. Hepatic insufficiency, acute alcohol intoxication, alcoholism

WARNING AND PRECAUTIONS:

Lactic acidosis:

Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure. The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.

Diagnosis:

The risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps with digestive disorders as abdominal pain and severe asthenia.

This can be followed by acidotic dyspnea, abdominal pain, hypothermia and coma.

Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/L, and an increased anion gap and lactate/pyruvate ratio. If metabolic acidosis is suspected, metformin should be discontinued and the patient should be hospitalised immediately.

Renal function:

As metformin is excreted by the kidney, creatinine clearance and/or serum creatinine levels should be determined before initiating treatment and regularly thereafter:

- at least annually in patients with normal renal function,
- at least two to four times a year in patients with creatinine clearance levels at the limit of normal and in elderly subjects.

Decreased renal function in elderly subjects is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive therapy or diuretic therapy and when starting therapy with an NSAID.

Administration of iodinated contrast agent:

As the intravenous administration of iodinated contrast materials in radiologic studies can lead to renal failure, metformin should be discontinued prior to, or at the time of the test and not reinstated until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal.

Surgery:

Metformin hydrochloride should be discontinued 48 hours before elective surgery with general spinal or peridural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition provided normal renal function has been established.

Other precautions:

- All patients should continue their diet with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.

- The usual laboratory tests for diabetes monitoring should be performed regularly.

- Metformin alone never causes hypoglycaemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. sulphonylureas or meglitinides).

- The tablet shells may be present in the faeces. Patients should be advised that this is normal.

Excipients

Lactose: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Effects on the Ability to Drive and Use Machines:

Metformin SR monotherapy does not cause hypoglycaemia and therefore has no effect on the ability to drive or to use machines.

However, patients should be alerted to the risk of hypoglycaemia when metformin is used in combination with other antidiabetic agents (sulphonylureas, insulin, or meglitinides).

ADVERSE EFFECTS:

In post marketing data and in controlled clinical studies, adverse event reporting in patients treated with Metformin SR was similar in nature and severity to that reported in patients treated with Metformin immediate release.

During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhoea, abdominal pain and loss of appetite, which resolve spontaneously in most case.

The following undesirable effects may occur with metformin:

Frequencies are defined as follows: very common: >1/10; common >1/100, <1/10; uncommon >1/1,000, <1/100; rare >1/10,000, <1/1,000; very rare <1/10,000 and isolated reports.

Nervous system disorders

Common: Taste disturbance

Gastrointestinal disorders

Very common : Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.

Skin and subcutaneous tissue disorders

Very rare : Skin reactions such as erythema, pruritus, urticaria

Metabolism and nutrition disorders

Very rare : Lactic acidosis. Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such aetiology is recommended if a patient presents with megaloblastic anaemia.

Hepatobiliary disorders:

Not known : Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.

"For suspected adverse drug reaction, report to FDA: www.fda.gov.ph or to TORRENT: www.torrentpharma.com".

Patient to seek medical attention immediately at the first sign of any adverse drug reaction shall appear.

OVERDOSAGE:

Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is haemodialysis.

DRUG INTERACTIONS:

Alcohol

Increased risk of lactic acidosis in acute alcohol intoxication, particularly in case of:

- fasting or malnutrition,

- hepatic insufficiency.

Avoid consumption of alcohol and alcohol-containing medications.

Iodinated contrast agents

Intravascular administration of iodinated contrast agents may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.

Metformin should be discontinued prior to, or at the time of the test and not reinstated until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal.

Combinations requiring precautions for use

Medicinal products with intrinsic hyperglycaemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics). More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.

Diuretics, especially loop diuretics.

They may increase the risk of lactic acidosis due to their potential to decrease renal function.

PREGNANCY AND LACTATION:

Pregnancy

Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.

A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development.

When the patient plans to become pregnant and during pregnancy, it is recommended that diabetes is not treated with metformin but insulin be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the foetus.

Breast feeding

Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast-feeding should be made, taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.

Fertility

Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human.

Preclinical Safety Data:

Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction.

CAUTION:

Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.

STORAGE CONDITION:

Store at temperatures not exceeding 30°C. Protect from light and moisture.

AVAILABILITY

Metformin Hydrochloride (Metta SR) 500 mg Extended-Release Tablet - Alu-Alu Blister pack of 10's (Box of 30's) - DRP-2445

DATE OF FIRST AUTHORIZATION

September 06, 2010

DATE OF REVISION

May 2016



Manufactured by :
TORRENT PHARMACEUTICALS LTD.
Indrad-382 721, Dist. Mehsana, INDIA.

Imported and Distributed by :
TORRENT PHARMA PHILIPPINES INC.
Units 3 & 4, 34th Floor, Zuellig Building
Makati Avenue Corner Paseo de Roxas
Makati City, PHILIPPINES

PRODUCT NAME	: Metta SR	COUNTRY : Philippines	LOCATION : Intrad	Supersedes A/W No.:			
ITEM / PACK	: Insert	NO. OF COLORS: 1	REMARK :				
DESIGN STYLE	: Front Back	PANTONE SHADE NOS.:	SUBSTRATE :				
CODE	: xxxxxxxx-5343	█ Black	Activities	Department	Name	Signature	Date
DIMENSIONS (MM) (LxWxH) :	180 x 240		Prepared By	Pkg.Dev			
ART WORK SIZE	: S/S		Reviewed By	Pkg.Dev			
DATE	: 17-06-2016		Approved By	Quality			